A closer look in skin toxicity of GCs in RMDs GC Toxicity Index, LONG TOX prospective cohort Frequent: -Easy bruising 35% -Atrophy 22% -Hirsutism 17% -Acneiform rash 15% -Erosion/Tear 12% GC-related Neuropsychiatric toxicity highly associated with/ skin, something to look out https://t.co/NfxG8JkxSP

• https://x.com/AurelieRheumo/status/1982523024923627796/photo/1
• https://x.com/AurelieRheumo/status/1982523024923627796/photo/1

Nice SRMA evaluating HCQ dosing >5mg/kg associated w/3.8x risk of retinopathy... ...but <5mg/kg associated w/1.8x risk of SLE flares Morbidity from one of those is easily avoided by regular screening; morbidity from the other can be devastating @RheumNow #ACR25 Abstr#805 https://t.co/1vJXxXqiRC

• https://x.com/EBRheum/status/1982522869562364407/photo/1

PD-1+ effector memory T cells in PsA synovium are functionally active and regulate Th17 cytokines via STAT3/RORγt. Recombinant PD-L1 agonist significantly reduced T cell proliferation and IL-17A/F/IL-22 production highlighting checkpoint agonists as a novel therapeutic strategy https://t.co/I6eNa0j7aa

• https://x.com/synovialjoints/status/1982522619220898224/photo/1

What is #nonadherence in #SLE associated with? 115 Pts w #lupus in Spain Overall medication adherence 58%! 👇Reduced if Male Low education No partner -NS adjusted analysis Unemployed Comorbidities 3 or more drugs/pills -NS adjusted #ACR25 @RheumNow @ACRheum #abst0216 https://t.co/CkG6gpiCw3

• https://x.com/Janetbirdope/status/1982521250959565160/photo/1

Two Jacks, One mission 🤓 Head on to the booth and get a chance to meet either one of them (both if you’re lucky, like me!) Continue tuning in for coverage of #ACR25 by the @RheumNow faculty and KOLs https://t.co/Y2pS8CpoH5

• https://x.com/RHEUMarampa/status/1982518851050037697/photo/1

CE study BEL vs csDMARDs in TriNetX Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analysis Pretty surprising given mediocre results from BLISS RCTs, but strong research group & lotsa fancy stats Do you believe it? #ACR25 @RheumNow Abstr#0804 https://t.co/Yex98EYDjP

• https://x.com/EBRheum/status/1982518842867015986/photo/1
• https://x.com/EBRheum/status/1982518842867015986/photo/1

#ACR25 Abstr#802 In #SLE pts with CLASI-A ≥8, pooled post-hoc analysis of Phase 2 RCT showed enpatoran, oral small molecule toll-like receptor 7/8-i impoved cutaneous response vs PBO as early as WK4. First-in-class promising therapy & warrant investigation in Phase 3 @RheumNow https://t.co/rn6NXdiGjD

• https://x.com/Yuz6Yusof/status/1982517785134854228/photo/1
• https://x.com/Yuz6Yusof/status/1982517785134854228/photo/1

Urinary proteomics reveals promising biomarkers for ankylosing spondylitis. PIK3IP1 & SDC1 levels were significantly elevated in AS patients, showing strong diagnostic performance (AUCs: 0.852 & 0.875). Combined with AMY1A, the multiplex panel reached an AUC of 0.973. Abstract https://t.co/YUulKFqj8V

• https://x.com/synovialjoints/status/1982515068551024689/photo/1

Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes -Diabetic nephropathy -Stage 3–5 CKD and reduced risk compared to TNFi treated and bionaive pts Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T

• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1
• https://x.com/AurelieRheumo/status/1982514480211693706/photo/1

The benefits of exercise has been proven for most rheumatic diseases, and there are lots of good reasons why #ACR25 Brian Andonian @RheumNow https://t.co/IEErXL6ynL

• https://x.com/drdavidliew/status/1982514009577570359/photo/1

What is my risk of developing proteinuria? Hopkins Lupus Cohort developed a risk score predicting 10-year risk of new-onset proteinuria after SLE dx (n=1,418) @RheumNow #ACR25 https://t.co/Z0zPrG2NJ3

• https://x.com/AkhilSoodMD/status/1982512551347859921/photo/1

#ACR25 Abstr#801 Post-hoc analysis of Phase 2 RCT showed longer duration on Ianalumab (IAN) is beneficial. More #SLE pts achieved LLDAS or DORIS remission and GC taper in IAN in blinded 28-wk phase + open label IAN for the next 24-week group vs PBO-Open Label IAN @RheumNow https://t.co/I1Ugfj3BBl

• https://x.com/Yuz6Yusof/status/1982512157893050797/photo/1

A retrospective study from Spain assessed the relationship bet HPV infxn & biologic tx in SLE pts 🔅 Prevalence of HPV 9.9% 🔅 No significant assocs bet HPV infxn, biologic tx, SLE-related dse variables & HPV RF progression Still, emphasize HPV screening #ACR25 @RheumNow Abs0659 https://t.co/1YusM1nYPr

• https://x.com/RHEUMarampa/status/1982511293178491235/photo/1

#0777 Big news for VEXAS! 🎯 The first validated disease activity index (VEXAS-DAI) has been developed via international Delphi consensus. A 12-domain, 40-point tool to standardise assessment & power trials in this complex syndrome. Validation underway! @RheumNow #ACR25 https://t.co/DSeHb7eNeV

• https://x.com/DrMiniDey/status/1982510034925015534/photo/1

Redefining When to Biopsy the Kidney in Patients with SLE # Petri et al. ACR 2025 - Lupus nephritis may be seen in lower proteinuria too (69%) Happy to share similar results from our study-Padiyar S, As C, Gowri M, Mathew J. Lupus. 2024;33(13):1511-1517. @RheumNow